DK3003385T3 - Antistofsammensætning og buffersystem til denne - Google Patents
Antistofsammensætning og buffersystem til denne Download PDFInfo
- Publication number
- DK3003385T3 DK3003385T3 DK14730479.4T DK14730479T DK3003385T3 DK 3003385 T3 DK3003385 T3 DK 3003385T3 DK 14730479 T DK14730479 T DK 14730479T DK 3003385 T3 DK3003385 T3 DK 3003385T3
- Authority
- DK
- Denmark
- Prior art keywords
- buffer system
- antibody composition
- antibody
- composition
- buffer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Ceramic Engineering (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1309759.7A GB2516808A (en) | 2013-05-31 | 2013-05-31 | Antibody composition and buffer system therefor |
| PCT/EP2014/061281 WO2014191560A1 (en) | 2013-05-31 | 2014-05-30 | Antibody composition and buffer system therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3003385T3 true DK3003385T3 (da) | 2020-01-06 |
Family
ID=48805557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14730479.4T DK3003385T3 (da) | 2013-05-31 | 2014-05-30 | Antistofsammensætning og buffersystem til denne |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11046753B2 (enExample) |
| EP (1) | EP3003385B1 (enExample) |
| JP (2) | JP2016530216A (enExample) |
| CN (1) | CN105592860B (enExample) |
| AU (1) | AU2014273034B2 (enExample) |
| DK (1) | DK3003385T3 (enExample) |
| ES (1) | ES2762501T3 (enExample) |
| GB (2) | GB2516808A (enExample) |
| WO (1) | WO2014191560A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170189548A1 (en) * | 2015-11-25 | 2017-07-06 | Immunogen, Inc. | Pharmaceutical formulations and methods of use thereof |
| KR102337683B1 (ko) * | 2018-09-21 | 2021-12-13 | 주식회사 녹십자 | 고효율 항-tfpi 항체 조성물 |
| CN111896752A (zh) * | 2020-08-11 | 2020-11-06 | 上海捷门生物技术有限公司 | 一种适用于多种poct类仪器的c-反应蛋白试剂盒 |
| CN113671188A (zh) * | 2021-08-10 | 2021-11-19 | 江南大学 | 一种检测贝类食品中河豚毒素的时间分辨免疫定量试纸条 |
| EP4218562A1 (en) | 2022-01-28 | 2023-08-02 | Charité - Universitätsmedizin Berlin | Real-time breath antigen detection system and method thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0516873A1 (en) | 1991-06-06 | 1992-12-09 | THE STATE of ISRAEL Atomic Energy Commission Soreq Nuclear Research Center | A method and kit for protein labelling with 99 mTC |
| ATE260674T1 (de) * | 1998-08-17 | 2004-03-15 | Pfizer Prod Inc | Stabilisierte proteinzusammensetzung |
| EP1871803B1 (en) * | 2005-04-18 | 2013-02-20 | Yeda Research And Development Company Limited | Stabilized anti-hepatitis b (hbv) antibody formulations |
| AU2006295340B2 (en) | 2005-08-05 | 2010-11-11 | Amgen Inc. | Stable aqueous protein or antibody pharmaceutical formulations and their preparation |
| CN101330931B (zh) * | 2005-12-12 | 2012-09-05 | 创新生物科学有限公司 | 制备缀合物 |
| WO2007074880A1 (ja) * | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
| CA2790018C (en) * | 2006-12-21 | 2015-02-03 | Amgen Inc. | Formulations |
| CN102089662B (zh) | 2008-07-16 | 2015-05-27 | 雷迪奥米特医学公司 | 高容量固相 |
| JP2011241206A (ja) | 2010-04-23 | 2011-12-01 | Arkray Inc | 標識抗体の安定化方法 |
| EP2583973B1 (en) | 2010-06-21 | 2018-03-21 | Kyowa Hakko Kirin Co., Ltd. | Method for purifying protein using amino acid |
| US8877892B2 (en) * | 2011-03-15 | 2014-11-04 | Innova Biosciences Limited | Conjugation reactions |
| EP2686334B2 (en) | 2011-03-16 | 2020-07-01 | F.Hoffmann-La Roche Ag | Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase |
| KR20120128440A (ko) | 2011-05-17 | 2012-11-27 | 삼성전자주식회사 | 표적 물질 검출용 키트 및 이를 이용한 표적 물질 검출 방법 |
-
2013
- 2013-05-31 GB GB1309759.7A patent/GB2516808A/en not_active Withdrawn
-
2014
- 2014-05-30 DK DK14730479.4T patent/DK3003385T3/da active
- 2014-05-30 US US14/894,828 patent/US11046753B2/en active Active
- 2014-05-30 AU AU2014273034A patent/AU2014273034B2/en active Active
- 2014-05-30 ES ES14730479T patent/ES2762501T3/es active Active
- 2014-05-30 WO PCT/EP2014/061281 patent/WO2014191560A1/en not_active Ceased
- 2014-05-30 GB GB1522774.7A patent/GB2530217A/en not_active Withdrawn
- 2014-05-30 JP JP2016516187A patent/JP2016530216A/ja active Pending
- 2014-05-30 CN CN201480043061.4A patent/CN105592860B/zh active Active
- 2014-05-30 EP EP14730479.4A patent/EP3003385B1/en active Active
-
2019
- 2019-09-09 JP JP2019163553A patent/JP2020007343A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB201309759D0 (en) | 2013-07-17 |
| GB201522774D0 (en) | 2016-02-03 |
| US11046753B2 (en) | 2021-06-29 |
| WO2014191560A1 (en) | 2014-12-04 |
| AU2014273034B2 (en) | 2019-11-21 |
| JP2016530216A (ja) | 2016-09-29 |
| ES2762501T8 (es) | 2020-06-18 |
| JP2020007343A (ja) | 2020-01-16 |
| US20160122416A1 (en) | 2016-05-05 |
| ES2762501T3 (es) | 2020-05-25 |
| AU2014273034A1 (en) | 2016-01-28 |
| CN105592860B (zh) | 2021-02-02 |
| GB2516808A (en) | 2015-02-11 |
| EP3003385B1 (en) | 2019-09-18 |
| GB2530217A (en) | 2016-03-16 |
| EP3003385A1 (en) | 2016-04-13 |
| CN105592860A (zh) | 2016-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290972A (en) | Anti-vista antibodies and fragments | |
| IL289821B (en) | Compositions and methods for immunotherapy | |
| DK3079719T3 (da) | ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3303394T3 (da) | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK2970460T3 (da) | Anti-IL-33-antistoffer og anvendelser deraf | |
| DK3026062T3 (da) | Anti-pd-1-antistof og anvendelse deraf | |
| DK3227336T3 (da) | Anti-CD79b-antistoffer og fremgangsmåder til anvendelse | |
| DK3258951T3 (da) | Anti-pvrig antistoffer og fremgangsmåder for anvendelse | |
| DK3083680T3 (da) | Humaniserede anti-Tau(pS422)-antistoffer og fremgangsmåder til anvendelse | |
| DK3008168T3 (da) | Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf | |
| DK3292150T3 (da) | Aktiverbare anti-cd166-antistoffer og fremgangsmåder til anvendelse deraf | |
| HUE055044T2 (hu) | MRNS-kódolt ellenanyagok bejuttatására szolgáló eljárások és készítmények | |
| LT3049441T (lt) | Anti-pdl1 antikūnų kompozicija | |
| DK3316909T3 (da) | Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder | |
| ME03675B (me) | Humanizovana ili himerna anтi-cd3 antiтela | |
| DK3192812T3 (da) | Anti-CD3-antistoffer og fremgangsmåder til anvendelse | |
| DK2996556T3 (da) | System til billedstyret procedure | |
| DK3116911T3 (da) | Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse | |
| DK3300745T3 (da) | Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf | |
| DK3086807T3 (da) | Antistoffer og fremgangsmåder til anvendelse | |
| DK2999103T3 (da) | Konverter og fremgangsmåde til styring deraf | |
| IL285527A (en) | Compositions and methods for immunotherapy | |
| DK3065771T3 (da) | Fremgangsmåder og sammensætninger til vedvarende immunterapi | |
| HUE051357T2 (hu) | IL-23 kötõ antitestek |